The FDA requires labeling changes to the prescribing information for Pfizer and GSK RSV vaccines to include warnings about the risk for GBS.
In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 could turn out.
1d
The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...
The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...
The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV ...
Hospitals in the USA are overwhelmed with a surge in patients due to a 'quad-demic' of flu, Covid-19, RSV, and norovirus.
On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk ...
As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...
U.S. approved the RSVpreF vaccine for adults 60 years and older in 2023, recommending it only based on individual’s decisions ...
Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...
The FDA has mandated updated safety labeling for two respiratory syncytial virus vaccines, Pfizer's Abrysvo and GlaxoSmithKline's Arexvy, following the identification of an increased risk of ...
The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback